Navigation Links
AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
Date:4/30/2008

monstrated in Phase 2 studies to provide fast and long-lasting relief of BPH symptoms while being well tolerated, with a low incidence of sexual side effects. Both BPH studies of cetrorelix presented in Milan were chaired by Prof. Frans M.J. Debruyne, M.D., Ph.D., former President of EAU, now Chairman and CEO of Andros Men's Health Institutes in The Netherlands.

Cetrorelix peptide-based drugs were developed by the Company in cooperation with Nobel Prize winner Prof. Andrew Schally, currently of the U.S. Veterans Administration in Miami.

Cetrorelix acetate is marketed under the brand name Cetrotide(R), the first LHRH antagonist approved for therapeutic use as part of in vitro fertilization programs (controlled ovarian stimulation/assisted reproductive technologies) in Europe, the U.S. and Japan. It was launched on the market through Serono (now Merck Serono) in the United States, Europe and in several other countries, as well as in Japan through Shionogi.

About the Cetrorelix Phase 3 Program in BPH

Cetrorelix pamoate is being studied in three Phase 3 trials which will include approximately 1,500 men with symptomatic BPH in the United States, Canada and Europe. One Phase 3 efficacy trial, primarily in the United States and Canada and with additional sites in Europe, involves approximately 600 patients (which are fully enrolled) and is being led by Herbert Lepor, M.D., Professor and Martin Spatz Chairman of Urology, New York University School of Medicine, New York. In the trial, patients enter a no-treatment run-in observation period to confirm severity and stability of voiding symptoms based on the International Prostate Symptom Score (I-PSS). Patients are then randomly allocated to cetrorelix or placebo in a double-blind fashion. Patients are administered cetrorelix by intra-muscular (IM) injection at Week 0, 2, 26 and 28 and are followed up to Week 52. Then, in an open-label extension, patients will receive cetrorelix by IM injection at W
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. AEterna Zentaris Partner, Spectrum, Provides Update on Ozarelix in Benign Prostatic Hyperplasia
2. AEterna Zentaris Completes Patient Recruitment for First Phase 3 Efficacy Trial with Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Announces Changes to its Management Team
4. AEterna Zentaris and Paladin Labs Complete Sale and Purchase of Miltefosine Rights
5. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
6. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
7. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
10. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
11. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... German-based Moenninghoff has designated the R.M. Hoffman ... Moenninghoff product line . , Moenninghoff ... that the R.M. Hoffman Company will be representing Moenninghoff ... 1916, this is a strategically important step. We ... professional distributor we need to successfully grow our business ...
(Date:6/1/2015)... , June 1, 2015  Turing Pharmaceuticals ... Eliseo Oreste Salinas , MD, MSc,  has joined ... Dr. Salinas, who holds a medical ... brings a record of significant accomplishments in the ... Dr. Salinas has played a leadership ...
(Date:6/1/2015)... RARITAN, N.J. , June 1, 2015 /PRNewswire/ ... from the Phase 3 multicenter study SAR3007, which ... with trabectedin (YONDELIS ® ) compared to dacarbazine ... (LMS) previously treated with an anthracycline and at ... largest randomized Phase 3 study ever conducted in ...
(Date:6/1/2015)... , June 1, 2015 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... March 31, 2015.  Biorem,s complete 2015 first quarter financial statements and ... Financial Summary:Three-months ended March 31,(in CDN$,000 except per share ... 4,689 , 1,974 Gross profit , 1,531 ... Net earnings (loss) , 528 , (531) Basic ...
Breaking Biology Technology:R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Biorem Reports Increased Revenues and Earnings for First Quarter 2Biorem Reports Increased Revenues and Earnings for First Quarter 3
... that a new market research report is available in ... 2010 http://www.reportlinker.com/p0481350/China-Bio-breeding-Industry-Report-2010.html ... China reached RMB 29.8 billion, up 4.9% from a ... capable of R&D independently, but they seem inferior when ...
... University, the Salk Institute for Biological Studies, and other ... patient,s own brain cells, which then can be studied ... brings researchers a step closer to understanding the biological ... be used to study other mysterious diseases such as ...
... cooperative research center program (I/UCRC) will "provide a one-stop ... wide range of metamaterials." Dr. David Crouse, associate ... Engineering at The City College of New York, serves ... Participating institutions are The City University of ...
Cached Biology Technology:Reportlinker Adds China Bio-breeding Industry Report, 2010 2Reportlinker Adds China Bio-breeding Industry Report, 2010 3Reportlinker Adds China Bio-breeding Industry Report, 2010 4Reportlinker Adds China Bio-breeding Industry Report, 2010 5Scientists recreate brain cells from skin cells to study schizophrenia safely 2Scientists recreate brain cells from skin cells to study schizophrenia safely 3Grove School professor leads new metamaterials center 2Grove School professor leads new metamaterials center 3Grove School professor leads new metamaterials center 4
(Date:5/26/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/p2kc6z/saudi_arabia ... "Saudi Arabia Biometric Systems Market Forecast and Opportunities, ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market in ... grow at over 22% CAGR through 2020 ... surging demand for better biometric technologies in the ...
(Date:5/21/2015)... , May 21, 2015 The Sync ... of music for health, today announced a collaborative partnership ... The partnership will center on collaboration on original research, ... first step in the collaboration, The Sync Project and ... "Music as Medicine" in the 2015-2016 academic year.  ...
(Date:5/19/2015)... , May 19, 2015 ... announced the addition of the  "Genetic Testing ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, ... in-depth analysis of the current and future ... gene-based tests, their working principles and types ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Global Genetic Testing Market Outlook 2018 2
... University research group has discovered that aggressive melanoma ... to proper embryo formation. , An article ... advanced online issue of the journal Nature Medicine. The ... growth factor by injecting aggressive melanoma cells into ...
... An ancient avenue for producing cellular energy, the glycolytic ... therapies. , A team of Harvard Medical School ... LDHA, in a variety of fast-growing breast cancer cells, ... mice. Control animals carrying tumor cells with an intact ...
... that may have broader implications for understanding kidney ... Philadelphia have identified a second gene that gives ... that affects multiple organs. The Children's Hospital team ... disease. , The researchers found that mutations in ...
Cached Biology News:Malignant melanoma cells secrete protein required for embryo formation 2Attacking cancer's sweet tooth is effective strategy against tumors 2Attacking cancer's sweet tooth is effective strategy against tumors 3Gene discovery may shed light on kidney disease 2
... Immulon 2HB ELISA strips, ... increased binding affinity for hydrophilic proteins ... works well for reagent injection while ... Each strip accomodates 12 ...
...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
... The 2.0 network client/server version of Freezerworks ... workflow in high-volume labs and facilitates the sharing ... to share sample information. ... PowerPC (100MHz, PPC 601); 13 in monitor with ...
Biology Products: